Literature DB >> 33476879

Estimating the causal effects of modifiable, non-genetic factors on Huntington disease progression using propensity score weighting.

Beth Ann Griffin1, Marika Suttorp Booth2, Monica Busse3, Edward J Wild4, Claude Setodji5, John H Warner6, Cristina Sampaio6, Amrita Mohan6.   

Abstract

INTRODUCTION: Despite being genetically inherited, it is unclear how non-genetic factors (e.g., substance use, employment) might contribute to the progression and severity of Huntington's disease (HD).
METHODS: We used propensity score (PS) weighting in a large (n = 2914) longitudinal dataset (Enroll-HD) to examine the impact of education, employment status, and use of tobacco, alcohol, and recreational and therapeutic drugs on HD progression. Each factor was investigated in isolation while controlling for 19 other factors to ensure that groups were balanced at baseline on potential confounders using PS weights. Outcomes were compared several years later using doubly robust models.
RESULTS: Our results highlighted cases where modifiable (non-genetic) factors - namely light and moderate alcohol use and employment - would have been associated with HD progression in models that did not use PS weights to control for baseline imbalances. These associations did not hold once we applied PS weights to balance baseline groups. We also found potential evidence of a protective effect of substance use (primarily marijuana use), and that those who needed antidepressant treatment were likely to progress faster than non-users.
CONCLUSIONS: Our study is the first to examine the effect of non-genetic factors on HD using a novel application of PS weighting. We show that previously-reported associated factors - including light and moderate alcohol use - are reduced and no longer significantly linked to HD progression after PS weighting. This indicates the potential value of PS weighting in examining non-genetic factors contributing to HD as well as in addressing the known biases that occur with observational data.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Disease progression; Huntington's disease; Non-genetic factors; Observational studies; Propensity scores

Mesh:

Substances:

Year:  2021        PMID: 33476879      PMCID: PMC7949328          DOI: 10.1016/j.parkreldis.2021.01.010

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  28 in total

1.  Challenges assessing clinical endpoints in early Huntington disease.

Authors:  Jane S Paulsen; Chiachi Wang; Kevin Duff; Roger Barker; Martha Nance; Leigh Beglinger; David Moser; Janet K Williams; Sheila Simpson; Douglas Langbehn; Daniel P van Kammen
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

2.  Substance abuse may be a risk factor for earlier onset of Huntington disease.

Authors:  Joanne A Byars; Leigh J Beglinger; David J Moser; Pedro Gonzalez-Alegre; Peg Nopoulos
Journal:  J Neurol       Date:  2012-01-25       Impact factor: 4.849

3.  Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease.

Authors:  Wenzhen Duan; Qi Peng; Naoki Masuda; Eric Ford; Erik Tryggestad; Bruce Ladenheim; Ming Zhao; Jean Lud Cadet; John Wong; Christopher A Ross
Journal:  Neurobiol Dis       Date:  2008-03-10       Impact factor: 5.996

4.  Earliest functional declines in Huntington disease.

Authors:  Leigh J Beglinger; Justin J F O'Rourke; Chiachi Wang; Douglas R Langbehn; Kevin Duff; Jane S Paulsen
Journal:  Psychiatry Res       Date:  2010-05-15       Impact factor: 3.222

5.  A retrospective study of the impact of lifestyle on age at onset of Huntington disease.

Authors:  M Kaye Trembath; Zoë A Horton; Lynette Tippett; Virginia Hogg; Veronica R Collins; Andrew Churchyard; Dennis Velakoulis; Richard Roxburgh; Martin B Delatycki
Journal:  Mov Disord       Date:  2010-07-30       Impact factor: 10.338

6.  Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine.

Authors:  Helen E Grote; Natalie D Bull; Monique L Howard; Anton van Dellen; Colin Blakemore; Perry F Bartlett; Anthony J Hannan
Journal:  Eur J Neurosci       Date:  2005-10       Impact factor: 3.386

7.  What is the impact of education on Huntington's disease?

Authors:  Jose Luis López-Sendón; Ana Royuela; Patricia Trigo; Michael Orth; Herwig Lange; Ralf Reilmann; Jennifer Keylock; Hugh Rickards; Silvia Piacentini; Ferdinando Squitieri; Bernhard Landwehrmeyer; Marie-Noelle Witjes-Ane; Caroline K Jurgens; Raymund A C Roos; Victor Abraira; Justo G de Yébenes
Journal:  Mov Disord       Date:  2011-03-22       Impact factor: 10.338

8.  Association between caffeine intake and age at onset in Huntington's disease.

Authors:  Clémence Simonin; Cécile Duru; Julia Salleron; Pascale Hincker; Perrine Charles; Arnaud Delval; Katia Youssov; Sylvie Burnouf; Jean-Philippe Azulay; Christophe Verny; Clarisse Scherer; Christine Tranchant; Cyril Goizet; Sabrina Debruxelles; Luc Defebvre; Bernard Sablonnière; Monique Romon-Rousseaux; Luc Buée; Alain Destée; Olivier Godefroy; Alexandra Dürr; Bernhard Landwehrmeyer; Anne-Catherine Bachoud-Levi; Florence Richard; David Blum; Pierre Krystkowiak
Journal:  Neurobiol Dis       Date:  2013-05-31       Impact factor: 5.996

9.  Motor, cognitive, and functional declines contribute to a single progressive factor in early HD.

Authors:  Scott A Schobel; Giuseppe Palermo; Peggy Auinger; Jeffrey D Long; Shiyang Ma; Omar S Khwaja; Dylan Trundell; Merit Cudkowicz; Steven Hersch; Cristina Sampaio; E Ray Dorsey; Blair R Leavitt; Karl D Kieburtz; Jeffrey J Sevigny; Douglas R Langbehn; Sarah J Tabrizi
Journal:  Neurology       Date:  2017-11-15       Impact factor: 9.910

10.  Sexually dimorphic serotonergic dysfunction in a mouse model of Huntington's disease and depression.

Authors:  Thibault Renoir; Michelle S Zajac; Xin Du; Terence Y Pang; Leah Leang; Caroline Chevarin; Laurence Lanfumey; Anthony J Hannan
Journal:  PLoS One       Date:  2011-07-08       Impact factor: 3.240

View more
  1 in total

Review 1.  Enroll-HD: An Integrated Clinical Research Platform and Worldwide Observational Study for Huntington's Disease.

Authors:  Swati Sathe; Jen Ware; Jamie Levey; Eileen Neacy; Robi Blumenstein; Simon Noble; Alzbeta Mühlbäck; Anne Rosser; G Bernhard Landwehrmeyer; Cristina Sampaio
Journal:  Front Neurol       Date:  2021-08-18       Impact factor: 4.086

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.